2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Neoplasm Metastasis
5
Cholangiocarcinoma
4
Stomach Neoplasms
3
Neoplasms
3
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced and Metastatic Urothelial Cancer
1
Interventions
Doxorubicin
19
Ifosfamide
12
Radiotherapy
11
pembrolizumab
6
Nivolumab
6
Ipilimumab
6
pazopanib
4
Specimen Handling
4
Radiation
4
Gemcitabine
4
Docetaxel
4
CTLA-4 Antigen
4
Biopsy
4
Trabectedin
3
Sunitinib
3
Magnetic Resonance Spectroscopy
3
pegfilgrastim
2
liposomal doxorubicin
2
cabozantinib
2
brostallicin
2
X-Rays
2
Radiotherapy, Conformal
2
Radiation Dose Hypofractionation
2
Methotrexate
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Diathermy
2
Cisplatin
2
Chemotherapy, Adjuvant
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
futibatinib
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled